Importantly, in both models of Chk1 inhibitor resistance, inhibition of their respective up-regulated pathways using small molecule inhibitors significantly decreases lymphoma size, suggesting a clinical target for Chk1 inhibitor-resistant cancers. This evidence concerns the gene CHEK1 and cancer.